Bleeding symptom assessment and hemostasis evaluation of menorrhagia

Current Opinion in Hematology

Volumn 15, Issue 5, 2008, Pages 465-472

  Kouides, Peter A ^a,b,c  

^a Mary M Gooley Hemophilia Center   (United States)

^b Roswell Park Memorial Cancer Institute   (United States)

^c ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Desmopressin; Menorrhagia; Postpartum hemorrhage; Von willebrand disease

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; ORAL CONTRACEPTIVE AGENT; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; EPISTAXIS; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMOSTASIS; HUMAN; LABORATORY TEST; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; MUSCLE HEMATOMA; PARTIAL THROMBOPLASTIN TIME; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SCORING SYSTEM; SYMPTOM; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; BLOOD CLOTTING PARAMETERS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; FEMALE;

FEMALE; HEMORRHAGE; HEMOSTASIS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MENORRHAGIA; PLATELET FUNCTION TESTS; VON WILLEBRAND FACTOR;

EID: 55249099821     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32830a4ed4     Document Type: Review

References (63)

1. James AH, Ragni MV, Picozzi VJ. Bleeding disorders in premenopausal women: (another) public health crisis for hematology? Hematology Am Soc Hematol Educ Program 2006:474-485.
2. Vessey MP, Villard-Mackintosh L, McPherson K, et al. The epidemiology of hysterectomy: findings in a large cohort study. BJOG 1992; 99:402-407.
3. Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82:405-422.
4. Shaw JA, Shaw HA. Menorrhagia. Emedicine 2007. http://www.emedicine. com/MED/topic1449.htm.
5. Doherty L, Harper A, Russell M. Menorrhagia management options. Ulster Med J 1995; 64:64-71.
6. Rees M. Menorrhagia. Br Med J (Clin Res Ed) 1987; 294:759-762.
7. Hallberg L, Nilsson L Determination of menstrual blood loss. Scand J Clin Lab Invest 1964; 16:244-248.
8. Shankar M, Lee CA, Sabin CA, et al. von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004; 111:734-740.
9. Mikhail S, Varadarajan R, Kouides PA. The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre. Haemophilia 2007; 13:627-632.
10. Philipp CS, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005; 105:61-66.
11. Philipp CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1:477-484.
12. Miller CH, Heit J, Kouides PA, et al. Laboratory characteristics of women with menorrhagia: a multisite U.S. study [abstract]. J Thromb Haemost 2007; 5 (Suppl 1).
13. Gulbas Z, Akay M, Akin A. Platelet dysfunction and other hemostatic abnormalities in iron deficient women with unexplained menorrhagia [abstract]. Blood 2001; 98:1056.
14. Hahn L, Cederblad G, Rybo G, et al. Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss. BJOG 1976; 83:974-980.
15. Winkler UH. Menstruation: extravascular fibrinolytic activity and reduced fibrinolytic capacity. Ann N Y Acad Sci 1992; 667:289-290.
16. Edlund M, Blomback M, He L. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis 2003; 14:593-598.
17. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, et al. Bleeding in carriers of hemophilia. Blood 2006; 108:52-56.
18. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243-1252.
19. Kadir RA, Economides DL, Sabin CA, et al. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5:40-48.
20. Ragni MV, Bontempo FA, Cortese Hassett A. von Willebrand disease and bleeding in women. Haemophilia 1999; 5:313-317.
21. Kouides PA, Burkhart P, Phatak P, et al. Gynecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6:643-648.
22. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss and iron deficiency. Acta Medica Scandinavica 1966; 180:639-650.
23. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85:977-982.
24. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. BJOG 1990; 97:734-739.
25. James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007; 5:1165-1169.
26. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101:2089-2093.
27. Sramek A, Eikenboom JC, Briet E, et al. Usefulness of patient interview in bleeding disorders [see comments]. Arch Intern Med 1995; 155:1409-1415.
28. Eikenboom JC, Rosendaal FR, Briet E. Value of the patient interview: all but consensus among haemostasis experts. Haemostasis 1992; 22:221-223.
29. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3:2619-2626.
30. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4:766-773.
31. Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007; 21:89-97.
32. Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007; 5 (Suppl 1):157-166.
33. Philipp CS, Faiz A, Dowling N, et al. Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol 2008; 198:163.e1-163.e8.
34. Chi C, Riddell A, Griffioen A, et al. Bleeding score as screening tool for the identification and assessment of von Willebrand disease in women [abstract]. Thromb Res 2007; 119 (Suppl 1):S101.
35. Fricke W, Kouides P, Kessler C, et al. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004; 2:763-768.
36. Montgomery RR, Coller BS. von Willebrand Disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis: basic principles and practice. Philadelphia: Lippincott Co.; 1994. pp. 134-168.
37. Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53:234-238.
38. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351:485-489.
39. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97:630-636.
40. Woo YL, White B, Corbally R, et al. von Willebrand's disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002; 13:89-93.
41. Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 2003; 88:EREP02.
42. Tosetto A, Rodeghiero F, Castaman G, et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2007; 5:715-721.
43. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study. Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 10:112-121.
44. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109:145-154.
45. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) 1. Haemophilia 2008; 14:171-232.
46. Lipton RA. Misdiagnosis by milk box. Haemophilia 2003; 9:235.
47. Bohm M, Taschner S, Kretzschmar E, et al. Cold storage of citrated whole blood induces drastic time dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17:39-46.
48. Abildgaard CF, Suzuki Z, Harrison J, et al. Serial studies in von Willebrand's disease: variability versus 'variants'. Blood 1980; 56:712-716.
49. Kouides PA. Aspects of the laboratory identification of von Willebrand disease in women. Semin Thromb Hemost 2006; 32:480-484.
50. Federici AB. Mild forms of von Willebrand disease: diagnosis and management. Curr Hematol Rep 2003; 2:373-380.
51. Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women [letter]. N Engl J Med 1980; 302:1093-1094.
52. Blomback M, Eneroth P, Landgren BM, et al. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992; 67:70-75.
53. Alperin JB. Estrogens and surgery in women with von Willebrand's disease. Am J Med 1982; 73:367-371.
54. Coccia MR, Barnes HV. Hypothyroidism and acquired von Willebrand disease. J Adolesc Health 1991; 12:152-154.
55. Blesing NE, Hambley H, McDonald GA. Acquired von Willebrand's disease and hypothyroidism: report of a case presenting with menorrhagia. Postgrad Med J 1990; 66:474-476.
56. Michiels JJ, Schroyens W, Berneman Z,Van der PM. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost 2001; 7:113-115.
57. Koscielny J, von Tempelhoff GF, Ziemer S, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10:155-166.
58. Posan E, Nichols WL, McBane RD, et al. Comparison of the PFA-100 testing and the bleeding time for detecting platelet hypofunction and von Willebrand disease. J Thromb Haemost 2003; 90:483-490.
59. Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2:892-898.
60. Philipp CS, Miller CH, Faiz A, et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia 2005; 11:497-503.
61. Bick RL. Platelet function defects: a clinical review. [Review] [238 refs]. Semin Thromb Hemost 1992; 18:167-185.
62. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33:39-45.
63. Smith AA, Jacobson LJ, Miller BI, et al. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112:329-337.